The gains came against a backdrop of falling net profits and cash reserves that will test Karolinska Development as it looks ahead to convertible debt obligations.
Karolinska Development, the investment arm of Karolinska Institute, witnessed a one-third annual increase in its portfolio value to SKr952m ($107.3m at December 31) in 2018 as it contemplated mixed operational fortunes at its biotech holdings. Karolinska Development’s net profit fell year-on-year in both annual terms and during the fourth quarter, sliding by 83% and 53.4%…
The rest of this content is only accessible to Global Venturing Subscribers.
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
